AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023

LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 CodeBreaK 200 Trial LUMAKRAS Shows Improved PFS vs Docetaxel Across Key Co-Alteration Subgroups in the Phase 3 CodeBreaK 200 Study…

Crocodile Was Top Predator At Newly Opened Prehistoric Site In Colorado

MORRISON, Colo., June 4, 2023 /PRNewswire/ — The landlocked state known for its towering Rocky Mountains and sprawling plains once featured dramatically different landscapes as seen in its geological formations. One of the more astonishing prehistoric Colorado sites is in Morrison on…

Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives

HONG KONG, June 4, 2023 /PRNewswire/ — The 4.5-star award-winning Dorsett Wanchai, Hong Kong is proud to lead the way for sustainability with its ‘GoGreen Promise’ and a series of paperless and plastic-free sustainability initiatives. As the Grand Award winner of the Hong Kong…

Sanyou launches new European offices and continues to promote global business landscape

SHANGHAI, June 3, 2023 /PRNewswire/ — In May 2023, following the CIC Boston branch in US, Sanyou opens new offices in The Shard London and CIC Rotterdam respectively, to rapidly promote the globalization of business landscape. Headquartered in Shanghai China, Sanyou Biopharmaceuticals Co….

Intensity Therapeutics’ INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6, a Locally Delivered Cytotoxic Treatment Leading to a Systemic Immune Response in Hot or Cold Tumors, Is A New Way To Treat Sarcoma…

Positive Shareholder Momentum Continues to Build In Support of Pelham Investment Partners LP’s Campaign to Change Board of Directors of Nickel 28 Capital Corp., With Support From Shareholders and ISS

Fellow shareholder Samara Capital Inc. holding voting control over approximately 7.4% of the issued and outstanding shares of Nickel 28 as of the record date, votes YELLOW Proxy “FOR” all Pelham’s director nominees ISS recognizes that “several credible governance and compensation issues…

ORCA’S PATENT-PENDING KIC (KEEP IT COOL) UNIVERSAL BEVERAGE HOLDER HEADLINES NEW DRINKWARE LINEUP

ORCA Also Releasing New Stein, Barrel And Rita Options NASHVILLE, Tenn., June 2, 2023 /PRNewswire/ — ORCA (Outdoor Recreation Company of America), a leading producer of roto-molded and soft-sided coolers and drinkware for people gathering together outdoors, announced its new summer…

Invivoscribe se asocia con Complete Genomics para desarrollar y comercializar pruebas de biomarcadores para oncología e investigación del cáncer

SAN DIEGO y SAN JOSÉ, California, 2 de junio de 2023 /PRNewswire/ — Invivoscribe y Complete Genomics anunciaron hoy que habían celebrado un acuerdo para desarrollar y comercializar pruebas de biomarcadores en las plataformas NGS de Complete Genomics. El territorio es mundial, y el campo…

VAN METRE COMPANIES CELEBRATES RECORD-BREAKING DONATION WITH 31ST ANNUAL 5K RUN FOR CHILDREN’S NATIONAL HOSPITAL

BROADLANDS, Va., June 2, 2023 /PRNewswire/ — Van Metre Companies hosted their 31st annual 5K Run and 1-Mile Fun Run supporting Children’s National Hospital. The event was held on April 29, 2023, in Broadlands, VA, and raised nearly $273,000, breaking their previous record for the cause….

Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary…

« Previous PageNext Page »